Ronald Witteles @Ron_Witteles Twitter profile

Last Seen Profiles

@Yellowcard

@Mhsnkrmzgl

@akhinzhanov

@lexilevermore

@StwTua

@dogeholders

@mjrobbins

@__SHESforever_

@TurntableKittah

@Habib10387326

@gummetes

@RDLee

@BlazeTV

@NevermindLis

@__fi2x

@MSGraser

@AbrahymT97905

@misogyny000

@NgaboRoben

@AngelTheTweak

@audreywongk

@TheWolvesReport

@ViictorCas

@Keana_wat

@320liltrick

@UWBiochemistry

@vavafle_cmsn

@aliamjadrizvi

@CMS_BB8

@ZenseiKun

@Zanfa

@trko_fr0be

@SerenityForge

@paul_wilder

@CoinCards

@CoachCHall

Ronald Witteles

@Ron_Witteles

3 years

1/ Thoughts/reflections on the events of the last 24 hours with the vaccine rollout at Stanford... One of the most upsetting 24 hours I have ever experienced.

28

115

675

Ronald Witteles

@Ron_Witteles

2 years

Lots of interesting #clinicaltrial results here at #ESCCongress for the #heartfailure world. A quick 🧵on those I felt were the most interesting & impactful...

10

132

414

Ronald Witteles

@Ron_Witteles

3 years

7/ I was proud to be one of those to take the pledge & cancelled my #vaccine spot today, as did so many of my colleagues throughout the @StanfordDeptMed , include every member of leadership. Our residents and fellows have started getting vaccinated instead, as it should be.

3

17

303

Ronald Witteles

@Ron_Witteles

10 months

Big news in the #amyloidosis world with the release of top line results for the Phase 3 #acoramidis trial, ATTRIBUTE-CM. Main message: It worked! 🍾 A lot of fascinating history behind this story. What else can we learn from the data? Details to follow… (1/14)

6

50

213

Ronald Witteles

@Ron_Witteles

1 year

🚨(1/9) STOP-CA trial reports positive results at #ACC23 , showing cardiac protection of atorvastatin for patients treated with anthracyclines. But last year’s similar trial was negative! What to believe?🤔A 🧵…

7

67

207

Ronald Witteles

@Ron_Witteles

3 years

4/ In an attempt to ensure equity, distribution was via an algorithm. This algorithm was well-intentioned but clearly hopelessly flawed. The lack of a sanity check being done on its output before it was put into action was a shocking and inexcusable error.

28

24

197

Ronald Witteles

@Ron_Witteles

3 years

2/ The rollout was an absolute mess. Pledges that were made were not followed through on. Housestaff were rightly upset to (for all practical purposes) be completely left out of the first wave. They are our very definition of frontline physicians.

3

7

176

Ronald Witteles

@Ron_Witteles

3 years

6/ I know there were many efforts across the institution today; I can tell you what we did in the DOM. We came together this morning and decided to ask all faculty except those at highest risk to give up their spots in line until all of our trainees could get vaccinated first.

1

12

171

Ronald Witteles

@Ron_Witteles

2 years

Congratulations to all of our amazing @StanfordMedRes residents on an incredible fellowship match! You make us all proud every day & I can’t wait to see all the great things you continue to do post-residency!!! 🎉🍾🥳 @StanfordDeptMed @HeartBobH @StanfordChiefs

2

14

165

Ronald Witteles

@Ron_Witteles

2 years

🍾 🎉 💥 Positively INCREDIBLE #MatchDay2022 for @StanfordMedRes ! Can’t wait to welcome this amazing group to @StanfordDeptMed in a few short months. Thank you to everyone who participated in this year’s recruitment! @HeartBobH @cuttingforstone @StanfordChiefs @KarinaSDelgadoC

5

26

165

Ronald Witteles

@Ron_Witteles

3 years

@DrNasrien @ManelWatchUS @ShelleyZieroth @DrMarthaGulati @hvanspall @amorrismd @KBreathettMD @kfmarie @JenHoCardiology @noshreza @ersied727 @Drroxmehran As far as I'm concerned, this is simply not acceptable in any field, much less one with so many great #WIC leaders as in heart failure. I have just withdrawn as a speaker. #NoManels

9

151

Ronald Witteles

@Ron_Witteles

3 years

9/ I couldn't be prouder of our @StanfordMedRes and @StanfordDeptMed fellows, who have stepped up all year in the face of this existential health crisis of our time. I more than understand their frustration/anger. I share it.

3

9

146

Ronald Witteles

@Ron_Witteles

3 years

10/ We had a town hall today for our residents/fellows. @AJRogers_ICU gave a particularly passionate/inspiring message about what our trainees have meant for our community. @HeartBobH spoke of our Department principles. And so proud of the thoughtful engagement of our housestaff.

12

140

Ronald Witteles

@Ron_Witteles

1 year

Absolutely overjoyed to share our incredible @StanfordMedRes #Match2023 . So excited to welcome this amazing group of physicians and physician-scientists to the @StanfordDeptMed family. Welcome!!! 🥳🎉🍾 @HeartBobH @PoonamHosamani @WendyCaceresMD @StanfordChiefs @AJRogers_ICU

9

25

140

Ronald Witteles

@Ron_Witteles

3 years

5/ The effect on housestaff was just one of the absurdities that occurred. Faculty members who are attending on COVID-only units were not included in Wave A, while others with little exposure were. There are more absurd examples than you can imagine.

2

9

134

Ronald Witteles

@Ron_Witteles

9 months

Celebrating the career of the best clinical Cardiologist I have ever known, and from whom I learned SO much — Dr. Michael Fowler, retiring after >40 years at @StanfordDeptMed . So much ❤️ in the room today from all of those he trained.

5

10

128

Ronald Witteles

@Ron_Witteles

5 years

So excited to serve as Associate Editor for the new @JACCJournals #JACCCardioOnc . Particularly lucky to work with great colleagues, including EIC Bonnie Ky, @DLenihanICOS_MD @AnaBaracCardio and many others. First issue later this year! @StanfordDeptMed @HeartBobH @ACCCardioEd

13

12

127

Ronald Witteles

@Ron_Witteles

9 months

(1/10) Today the long-awaited full results from the Phase 3 ATTRibute-CM trial were presented @escardio #ESCCongress . We already knew the topline results from last month: Acoramidis made a (big) difference in outcomes! What more did we learn?🤔Let's dig deeper...

1

47

124

Ronald Witteles

@Ron_Witteles

3 years

It's finally here -- the #Amyloidosis Special Issue from @JACCJournals #JACCCardioOnc ! The quality of the manuscripts surpasses anything we could have hoped for. Thank you to all authors & reviewers! Specific highlights below...

2

34

121

Ronald Witteles

@Ron_Witteles

3 years

8/ I have so much sadness over today. Sadness for the message that it seemed to send to our trainees, even if not deliberate. Sadness to miss out on the joy of celebrating the monumental achievement of the vaccine with the #IGotTheShot picture I've been excited about all week.

3

7

120

Ronald Witteles

@Ron_Witteles

2 years

(1/9) A few thoughts re: today’s topline results for #acoramidis (AG10) @BridgeBioPharma for #ATTR #amyloidosis . The big takeaway — results are less surprising than first meet the eye, and should not be taken to mean the drug won’t work.

Heart drug's trial failure busts bid to best Pfizer, but BridgeBio still bets on coming data -...

BridgeBio reported its drug acoramidis missed the main goal of a pivotal study in patients with transthyretin amyloidosis affecting the heart—the same type of patients helped by a currently approved...

medcitynews.com

7

26

118

Ronald Witteles

@Ron_Witteles

3 years

Truly DELIGHTED to welcome the newest members of the @StanfordMedRes and @StanfordDeptMed family. What an ABSOLUTELY INCREDIBLE group! Congratulations to all on #MatchDay2021 ! 🍾🎉 @HeartBobH @cuttingforstone @WendyCaceresMD @AJRogers_ICU @PoonamHosamani @StanfordChiefs

4

15

113

Ronald Witteles

@Ron_Witteles

2 months

Elated to welcome an incredible group of physicians & physican-scientists to @StanfordMedRes -- the 2024-2025 intern class! We can't wait to welcome you to the @StanfordDeptMed family in 3 short months!🍾🎉 #Match2024 @StanfordChiefs @trepraja04 @KarinaSDelgadoC @PoonamHosamani

0

16

109

Ronald Witteles

@Ron_Witteles

4 years

Huge news in AL #amyloidosis ! #Daratumumab shows massive improvements in complete hematologic response (53% vs. 18%!) in upfront treatment when combined w/CyBorD vs CyBorD alone. Awaiting full data, of course, but expect this will be new SOC. #ANDROMEDA

Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-ch...

Company Announcement Phase III ANDROMEDA study of subcutaneous daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone for patients...

www.globenewswire.com

3

34

107

Ronald Witteles

@Ron_Witteles

7 months

(1/11) The @US_FDA has denied the sNDA for #patisiran for an indication for #ATTR -CM, based on the APOLLO-B trial. 😮One can respect the process but disagree with the result -- and I think this was a major miss by @US_FDA . A brief🧵... #amyloidosis

Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA)

www.businesswire.com

7

38

104

Ronald Witteles

@Ron_Witteles

1 year

(1/9) Exciting news in the #ATTR #Amyloidosis world with the publication of this Phase 1 trial of #NI006 for amyloid removal. Is this the next big thing? Is it a lot of hype? A 🧵...

NEJM

@NEJM

1 year

Late breaking at #HeartFailure2023 : In a phase 1 trial, NI006 had a favorable safety profile in patients with transthyretin amyloid cardiomyopathy. At doses of at least 10 mg per kilogram, amyloid-load surrogates appeared to be reduced.

5

101

279

1

33

107

Ronald Witteles

@Ron_Witteles

11 months

New #ImpactFactor release today, and 🤯 WOW!!! @JACCJournals #JACC :CardioOnc up to IF of 11.1 !?!? For a journal not even 4 years old? A testament to the inspired leadership of #BonnieKy . So privileged to work w/her & the rest of the editorial team. 🍾🎈🎉 #CardioOnc

5

15

103

Ronald Witteles

@Ron_Witteles

3 years

Best day of the year? Welcoming a new class to the @StanfordMedRes family! Can’t wait to work with you and see all of the amazing things you will do. @StanfordDeptMed @HeartBobH @cuttingforstone @AJRogers_ICU @PoonamHosamani @WendyCaceresMD @andreajonasmd @KarinaSDelgadoC

2

18

93

Ronald Witteles

@Ron_Witteles

3 years

3/ There will need to be a deep dive into how exactly this happened. I am at least happy to say that I have learned enough over the course of the day to know that this was not malice or a specific intent to exclude the housestaff. (cont.)

5

7

94

Ronald Witteles

@Ron_Witteles

2 years

Exciting news in the #amyloidosis world with the success of APOLLO-B showing the success of a #silencer treatment ( #patisiran ) for the first time in a Phase 3 study designed for #ATTR -CM. 🍾 Several thoughts to follow…

Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the APOLLO-B Phase 3 study of patisiran, an

www.businesswire.com

1

28

92

Ronald Witteles

@Ron_Witteles

2 years

Congrats to the investigators on this impressive & important study. Statins do not attenuate doxorubicin-induced LVEF drops in this careful evaluation. More thoughts to follow… #CardioOnc @NEJM

Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment

evidence.nejm.org

1

24

90

Ronald Witteles

@Ron_Witteles

4 years

Proud to see our latest research on ❤️ #transplant outcomes in #amyloidosis patients published today in @JACCJournals JACC:HF. Outcomes in 31 consecutive transplanted patients have been excellent. Key takeaways to follow:

3

25

88

Ronald Witteles

@Ron_Witteles

6 months

You think #amyloidosis is 🔥right now? This is a picture from the amyloidosis/HFpEf session 5 minutes BEFORE the session even started! 😮 Terrific presentations and discussions by all! @MasriAhmadMD @mvaduganathan @DrNancySweitzer @noshreza @MkosiborodMD @jvaishnavmd @amorrismd

2

5

86

Ronald Witteles

@Ron_Witteles

9 months

The fondest of farewells to an amazing mentor and friend @HeartBobH , finishing his tenure as Chair at @StanfordDeptMed . Our Department simply could not have had a better leader. Thank you on behalf of @StanfordMedRes & the entire education team!

1

8

83

Ronald Witteles

@Ron_Witteles

2 years

Catching up with @StanfordMedRes superstar intern @MMoscvin at the amyloidosis #ISA_2022 meeting in Germany! 🇩🇪 So proud of Maria, who is giving an oral presentation to the sold-out auditorium of 1000+ people on Tuesday. No pressure! 😉 @TheBianchiLab @RonglihL @StanfordDeptMed

2

8

79

Ronald Witteles

@Ron_Witteles

7 months

The #sarcoidosis session at #HFSA2023 this morning was truly fantastic. Great talks, tons of energy in the room, and absolutely packed! A discipline on the verge of exploding? 🧨 We’ll need a bigger room next year, @HFSA ! 😉 @ChonyAlbertMD @sanjaydivakaran @ngilotraMD

2

10

77

Ronald Witteles

@Ron_Witteles

1 year

SO excited to announce the @StanfordMedRes 2024-2025 Chief Residents! @CelesteWitting @hayleygalitzer #VishnuNair & #SulaimanSomani are going to be incredible @StanfordChiefs . Congratulations!!! 🎈🍾🎉 @StanfordDeptMed @HeartBobH @WendyCaceresMD @PoonamHosamani @AJRogers_ICU

0

5

78

Ronald Witteles

@Ron_Witteles

2 years

Best 12 hour stretch in recent memory? First a @warriors 🏆, then welcoming the new @StanfordDeptMed interns to the @StanfordMedRes family. Life is good!!! @HeartBobH @cuttingforstone @StanfordChiefs @WendyCaceresMD @AJRogers_ICU @PoonamHosamani @KarinaSDelgadoC @trepraja04

2

6

72

Ronald Witteles

@Ron_Witteles

3 years

Such a fun night celebrating our incredible 2020-2021 @StanfordChiefs last night. Here they are w/the proprietary Vista Verde Vineyards🍷 blend from @HeartBobH — 2017 vintage, the year they started as interns! Thank you @DrMitaHopp @adriancast2 #AndrewMoore ! @StanfordDeptMed

2

6

75

Ronald Witteles

@Ron_Witteles

2 years

Better late than never! End-of-Chief-Year dinner with the INCREDIBLE 2019-2020 @StanfordChiefs @Surbhi_Singhal2 @beccatis @Amy_R_Filsoof , after a 2-year pandemic delay. Nobody could have led the program with more skill or grace. @AJRogers_ICU @HeartBobH @StanfordMedRes

3

74

Ronald Witteles

@Ron_Witteles

9 months

(1/2) Huge congrats to the AMAZING #SulaimanSomani , @StanfordMedRes PGY-3 and future @StanfordChiefs , on his #ESCCongress presentation validating the “W-S” method for #LVH detection on the ECG. The beauty is in its simplicity — QRS complexes running into one another! 😮😮😮

2

7

73

Ronald Witteles

@Ron_Witteles

3 years

CONGRATULATIONS to the 2021 @StanfordMedRes graduates. You have inspired us all - caring for your patients, caring for the community, and caring for one another. Can't wait to see all of the incredible things you do! @HeartBobH @StanfordDeptMed @cuttingforstone @KarinaSDelgadoC

1

4

72

Ronald Witteles

@Ron_Witteles

5 years

This is FAR too simplistic. Not particularly useful for cardiogenic shock NOS, but can be life-saving for cardiogenic shock due to refractory ischemia, acute MR, or acute VSD. Let’s not throw the baby out with the bath water! #IABP #CCU @HFSA

Andrew M. Goldsweig, MD, MS

@AGoldsweig

5 years

ESC Guidelines: IABP does NOTHING! #CRT2019

12

59

107

6

18

72

Ronald Witteles

@Ron_Witteles

2 years

2) Another nail in the coffin for #PCI improving #heartfailure outcomes. ABSOLUTELY no difference in death or HF hospitalization (p=0.96) with PCI, even despite viability testing. PCI is for angina & ACS, not heart failure! Now, will it change practice???

Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction | NEJM

Whether revascularization by percutaneous coronary intervention (PCI) can improve event-free survival and left ventricular function in patients with severe ischemic left ventricular systolic dysfun...

www.nejm.org

3

14

71

Ronald Witteles

@Ron_Witteles

6 years

Truly incredible result for this landmark trial in #ATTR #amyloidosis . I cannot emphasize enough what a home run this is for patients with this not-even-remotely-rare disease. A privilege to take part in this study. More thoughts to follow. #StanfordAmyloidCenter #tafamidis

NEJM

@NEJM

6 years

ATTR-ACT: This phase 3 RCT of tafamidis to treat transthyretin amyloid cardiomyopathy reduced, in combination, all-cause mortality and CV-related hospitalizations. It also reduced declines in functional capacity and quality of life. #ESCCongress

4

101

146

2

29

69

Ronald Witteles

@Ron_Witteles

2 years

Great to spend some time with superstar @StanfordMedRes & @StanCVFellows graduate @David_Ouyang at #ESCCongress . David is a true leader in Cardiology #ArtificialIntelligence — a field of great promise, particularly around #amyloidosis screening. @StanfordDeptMed @Paul_P_Cheng

1

6

69

Ronald Witteles

@Ron_Witteles

10 months

Really nice thought-provoking work by @dineshpmcc1 & colleagues in @JACCJournals : #CardioOnc examining #SGLT2 inhibitors & cardioprotection in #anthracycline treated patients. 🤔Good rationale for randomized trials. Congrats!

2

13

68

Ronald Witteles

@Ron_Witteles

2 years

BIG news in the amyloidosis world. Next stop: ATTR: cardiomyopathy? #amyloidosis #StanfordAmyloidCenter @KMAlexanderMD @RonglihL @MarthaGrogan1 @maz_hanna @mathew_maurer @JigPatelMDPhD @Paul_P_Cheng @MKIttlesonMD

Amyloidosis Research Consortium

@Amyloidosis_ARC

2 years

BREAKING NEWS: AMVUTTRA (vutrisiran) approved by FDA for the treatment of hereditary ATTR #amyloidosis with polyneuropathy. This approval expands the available treatment options for patients. Congratulations @Alnylam

1

35

72

1

13

68

Ronald Witteles

@Ron_Witteles

3 years

Gene editing in #ATTR #amyloidosis : SO exciting. In many ways the “perfect” condition for it - a disease driven by a single protein, with a track record of lowering the protein levels being an effective Rx. The future is now. #StanfordAmyloidCenter

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis | NEJM

Transthyretin amyloidosis, also called ATTR amyloidosis, is a life-threatening disease characterized by progressive accumulation of misfolded transthyretin (TTR) protein in tissues, predominantly t...

www.nejm.org

1

12

69

Ronald Witteles

@Ron_Witteles

3 years

A brief thread on the landmark SUCCOUR trial published in this week's @JACCJournals ... Link to the article & the editorial I had the privilege of coauthoring with @CardioOncology below. (1/10) #CardioOnc

2

27

65

Ronald Witteles

@Ron_Witteles

2 years

SO GREAT to be back in person for the Annual @StanfordMedRes Research Symposium! Incredible event, amazing turnout by residents/faculty, so much joy! 😀 Amazed by the incredible work of our residents every year. @AJRogers_ICU @HeartBobH @StanfordDeptMed @JoyYWu @StanfordChiefs

1

7

67

Ronald Witteles

@Ron_Witteles

4 years

Thank you - this is really humbling. Incredible colleagues in program leadership including APD team, program coordinators, and the amazing @StanfordChiefs over the years. Sincerely appreciate all the kind words. @StanfordDeptMed @StanfordMedRes @HeartBobH

Stanford Department of Medicine

@StanfordDeptMed

4 years

Congrats to @StanfordMedRes Director @Ron_Witteles , who received Stanford Graduate Medical Education’s 2020 Program Director of the Year Award. Ron was recognized for his "leadership, advocacy for residents, and his creativity in addressing challenges and devising curricula.”

7

10

83

5

2

66

Ronald Witteles

@Ron_Witteles

2 years

1) Another win for #SGLT2i in #HFpEF , this time for dapagliflozin. For those who quibble with the HFpEF definition (LVEF>40%), look at the subgroup analysis -- jut as impactful for patients with truly normal LVEFs as those with mild systolic dysfunction.

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | NEJM

Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejec...

www.nejm.org

2

13

67

Ronald Witteles

@Ron_Witteles

2 years

4) #ArtificialIntelligence beats sonographers for LVEF assessment in a well-designed study by @DavidOuyang . Really impressive data -- time to integrate into practice?

EchoNet AI Algorithm Beats Sonographers for Estimating LV Function

In what investigators say is the first randomized, controlled trial of AI in cardiology, big data boosted accuracy and efficiency.

www.tctmd.com

1

8

64

Ronald Witteles

@Ron_Witteles

1 year

Congratulations to @HeartBobH for his new role, & to @Cornell for an incredible choice! 🍾 I have had the privilege of working with @HeartBobH for the past 11 years and have learned SO much from his wisdom, vision, and leadership. Thank you! 🙏 @StanfordDeptMed @StanfordMedRes

Cornell University

@Cornell

1 year

Dr. Robert Harrington @HeartBobH , a cardiologist and Professor of Medicine and chair of the Department of Medicine at Stanford University, will serve as the next Stephen and Suzanne Weiss Dean of @WeillCornell Medicine.

75

64

612

1

2

63

Ronald Witteles

@Ron_Witteles

4 years

Delighted to announce the 2021-2022 @StanfordMedRes Chief Residents: @jkbuesing @achyut_patil_ @gabrielamabel12 & Zach Gray. Really looking forward to working with this incredibly talented group! @StanfordDeptMed @HeartBobH @cuttingforstone @StanfordChiefs @KarinaSDelgadoC

2

10

61

Ronald Witteles

@Ron_Witteles

1 year

Always the best part of any meeting - spending time with colleagues! Great dinner with @StanfordMedRes PGY-2 @StefanTorelli & alum/physician-scientist extraordinaire @HanZhuMD at the @ACCinTouch 🫀 #CardioOnc meeting in DC. @Paul_P_Cheng @JuneWRhee @StanfordDeptMed @HeartBobH

1

7

63

Ronald Witteles

@Ron_Witteles

2 years

3) Very interesting study showing better inpatient decongestion for ADHF patients with addition of #acetazolamide to loop diuretics. No change in mortality or HF rehospitalization, but better decongestion at 3 days. Practice changing for ADHF?

Acetazolamide in Acute Decompensated Heart Failure with Volume Overload | NEJM

Whether acetazolamide, a carbonic anhydrase inhibitor that reduces proximal tubular sodium reabsorption, can improve the efficiency of loop diuretics, potentially leading to more and faster deconge...

www.nejm.org

3

11

61

Ronald Witteles

@Ron_Witteles

11 months

The joy of academic medicine — bidding farewell to an amazing graduating class @StanfordMedRes & welcoming the next incredible group to @StanfordDeptMed today! Such excitement in the air!🍾🎉 @HeartBobH @abe_verghese @WendyCaceresMD @andreajonasmd @PoonamHosamani @StanfordChiefs

0

5

62

Ronald Witteles

@Ron_Witteles

3 years

Don’t make a catastrophic mistake w/free light chain interpretation! Proud to present this handy guide, in collaboration w/Michaela Liedtke, published in @CircHF . One of the most common mistakes in #ATTR #amyloidosis eval. Don’t let this happen to you! @StanfordDeptMed @RonglihL

Edgardo Alania

@Ed_Alania

3 years

🔴Avoiding Catastrophe: Understanding Free Light Chain Testing in the Evaluation of ATTR Amyloidosis @Ron_Witteles @CircHF #CardioEd #Cardiology @SantasEnrique @drahmedmohsen85 @MasriAhmadMD @maz_hanna @MarthaGrogan1 @AlessiaArgiro @Cardioinfo_it @torresviera @dra_hlara @ResiSec

2

33

83

1

19

62

Ronald Witteles

@Ron_Witteles

1 month

The best kind of start to #ACC24 . Dinner with two @StanfordMedRes super⭐️ residents, and then breakfast catching up with @HeartBobH . What meetings are all about! @StanfordDeptMed @StanfordChiefs

0

3

61

Ronald Witteles

@Ron_Witteles

2 years

Only the second Impact Factor #JACCCardioOnc - and already at 8.422! 🤯 Now a top-25 journal in all of #Cardiology ! 🍾💥 A privilege to work with #BonnieKy and the entire Editorial team. @JACCJournals #CardioOnc

1

10

59

Ronald Witteles

@Ron_Witteles

2 years

6) Can't be said enough: Each one of these results represents tremendous work by the investigators. Medicine moves forward only with good data, and successfully completing large clinical trials is HARD. Congrats to all. Now let's #followtheevidence !

1

9

57

Ronald Witteles

@Ron_Witteles

4 years

Incredibly proud of our @StanfordMedRes residents! 25 presentations tonight at our Resident Research Symposium, all via Zoom, in the middle of a pandemic. Superb @StanfordDeptMed faculty engagement too. Thank you! @HeartBobH @AJRogers_ICU @SWaliany @FaRodriguezMD @joshuawknowles

0

12

60

Ronald Witteles

@Ron_Witteles

4 years

Incredible, amazing, spectacular (running out of adjectives) #Match2020 for @StanfordMedRes . So excited to welcome this exceptional group of physicians & physician-scientists to the @StanfordDeptMed family! @HeartBobH @WendyCaceresMD @PoonamHosamani @cuttingforstone

3

13

55

Ronald Witteles

@Ron_Witteles

11 months

Why is late June the best ⏰ of the year? Because that’s when we welcome our new @StanfordMedRes interns to campus! Thank you #TejaPatil for letting me crash your APD dinner group tonight, and welcome to our amazing new interns!!! @StanfordDeptMed @HeartBobH @StanfordChiefs

5

1

57

Ronald Witteles

@Ron_Witteles

4 years

🚨🚨🚨Major issue with #CABANA randomization uncovered by @StanCVFellows . A randomization finding with a P-value of 5.5 x 10E-6 (!!!) was discovered, and as far as I know, has not been commented on before. Please unroll the thread -- I don't think you'll be disappointed...

4

14

56

Ronald Witteles

@Ron_Witteles

3 years

Fun (though bittersweet!) evening bidding farewell to rising #CardioOnc phys-scientist superstar @JuneWRhee who has a great opportunity @cityofhope . Look forward to many collaborations! @SeanM_Wu @Paul_P_Cheng @HanZhuMD @SWaliany @StanfordMedRes @StanfordCVI @StanfordDeptMed

2

57

Ronald Witteles

@Ron_Witteles

2 years

A fond farewell to APD-extraordinaire Shri Nallamshetty who is starting a new leadership position at #PaloAltoVA . Over the last 8.5 years, Shri’s wisdom & leadership have meant so much to our program and our @StanfordMedRes residents. Thank you Shri! @StanfordDeptMed @HeartBobH

0

7

55

Ronald Witteles

@Ron_Witteles

6 years

A friendly reminder for all contemplating their match lists during this residency interview season... @StanfordMedRes #Match2018

James Januzzi Jr MD

@JJheart_doc

6 years

This week in Boston: Monday: Incredibly cold Tuesday: Ridiculously cold Wednesday: Less ridiculously cold...but wait... Thursday: A foot of snow with blizzard conditions Friday: Record setting cold Saturday: Surface of Mars cold Sunday: dont-even-think-about-going outside cold

6

46

150

3

12

52

Ronald Witteles

@Ron_Witteles

2 years

5) Not a clinical trial, but the first ever #ESC #CardioOncology guidelines were released. Congrats to the group who worked so hard to make this reality. More thoughts to come in #JACCCardioOnc . @dineshpmcc1 @CardioOncology

1

7

53

Ronald Witteles

@Ron_Witteles

6 years

Really big news today in the world of ATTR #amyloidosis with the FDA approval of #Alnylam -developed medication #patisiran . Widely expected of course, but a huge milestone for our field nonetheless. A few thoughts to follow...

5

20

54

Ronald Witteles

@Ron_Witteles

4 years

Excited to be participating in this multi-institution #CardioOnc conference next week, including presentations by @StanfordMedRes and @StanCVFellows superstars @SWaliany & @HanZhuMD . Go team science! @CardioOncology @JuneWRhee @SeanM_Wu @StanfordDeptMed @sandysrimd @Paul_P_Cheng

1

15

52

Ronald Witteles

@Ron_Witteles

2 years

Wonderful night celebrating this year’s incredible @StanfordChiefs ! The 💯 best part of being PD is working with amazing #ChiefResidents every year. Thank you @gabrielamabel12 @jkbuesing @achyut_patil_ & #ZachGray ! @HeartBobH @cuttingforstone @StanfordDeptMed @StanfordMedRes

0

4

52

Ronald Witteles

@Ron_Witteles

1 year

(1/5) We have a new leader in the clubhouse for #cardiac #stemcell hype>>>science. A well-done trial which the investigators deserve great credit for conducting... But the spin & media portrayal of the study results is positively🤯.

10

3

52

Ronald Witteles

@Ron_Witteles

5 years

Honored to be a co-author on these recommendations for #ATTR #amyloidosis . A truly exciting time for advances in the diagnosis and treatment of this deadly disease. #StanfordAmyloidCenter @MathewMaurer @MarthaGrogan1 @maz_hanna @i_lousada @RonglihL @KMAlexanderMD

Circ: Heart Failure

@CircHF

5 years

In a new #AdvancesinHF review, see expert recommendations for earlier diagnosis of cardiac ATTR amyloidosis, a progressive, underrecognized disease @Amyloidosis_ARC @MathewMaurer #AHAJournals |

0

15

25

1

17

52

Ronald Witteles

@Ron_Witteles

2 years

No surprise that @StanfordMedRes PGY-1 @MMoscvin hit it out of the park with her presentation on botulinum toxin/light chain secretion in AL #amyloidosis at #ISA_2022 . Congratulations Maria! 🎉 🍾 @StanfordDeptMed @TheBianchiLab @RonglihL @KMAlexanderMD @Paul_P_Cheng

0

7

50

Ronald Witteles

@Ron_Witteles

1 year

Proud to present the November 2022 mini-focus issue on #amyloidosis in @JACCJournals #JACCCardioOncology . Follows up last year’s fantastic Amyloidosis special issue. Check it out! 🥳

1

11

49

Ronald Witteles

@Ron_Witteles

6 years

Big ego boost this AM. Rounding w/ @YaleCardiology CCU team who had admitted a patient w/tamponade. They had gone to @StanfordMed25 website overnight to learn how to measure pulsus paradoxus. 100% coincidence & they couldn’t believe that “the guy from the website” was on rounds!

2

8

50

Ronald Witteles

@Ron_Witteles

2 years

Pinch hitting for @andreajonasmd welcoming her APD group of new @StanfordMedRes interns over pizza, burrata, and Prosecco. A tough job but someone’s gotta do it! 😉 Welcome to the @StanfordDeptMed family! 🍕 🍾 @HeartBobH @StanfordChiefs @PJuthani @ParanjpeIshan @Terunpizza

3

7

47

Ronald Witteles

@Ron_Witteles

1 year

Great showing by @StanfordMedRes and @StanCVFellows at #ACC23 ! Congratulations on all of your studies & achievements! 🥳 @StanfordDeptMed @HeartBobH @EldrinL @FaRodriguezMD @AshishSarraju @KrishnaPundi @AllisonWPeng @yaanikdesai @joshuawknowles

1

9

47

Ronald Witteles

@Ron_Witteles

5 years

A privilege for @StanfordDeptMed to host U. Penn for the #stanfordpenn2019 CV conference. Particularly great to catch up w/ @JACCJournals #JACCCardioOncology EIC Bonnie Ky, who gave a great talk on the state of the field. #amyloidosis @StanfordCVI @HeartBobH @JuneWRhee @SeanM_Wu

0

10

50

Ronald Witteles

@Ron_Witteles

4 years

Working with #ChiefResidents is the not-so-secret best part of being Program Director. Felt like a reunion today meeting with last year’s simply incredible group to discuss a Med Ed manuscript — @Amy_R_Filsoof @Surbhi_Singhal2 & @beccatis . Stay tuned! @HeartBobH @StanfordMedRes

0

2

48

Ronald Witteles

@Ron_Witteles

3 years

Interested in♥️ #transplant or #MCS for patients with #amylodiosis ? Check out this Primer in the latest issue of #JACCCardioOncology ! @JACCJournals

0

17

46

Ronald Witteles

@Ron_Witteles

1 year

With #InternalMedicine #residency season coming to a close, I thought it was worth tapping into the #ChatGPT craze to see what #ArtificialIntelligence has to say about @StanfordMedRes . Results ⬇️. Not bad!!! (Other than the pediatrics line...) @StanfordDeptMed @StanfordChiefs

0

8

47

Ronald Witteles

@Ron_Witteles

2 years

#CongoRed ! Yessssssssss! Was there any other acceptable answer? #amyloidosis

Dr. Glaucomflecken

@DGlaucomflecken

2 years

The pathology residency interview

347

2K

18K

1

48

Ronald Witteles

@Ron_Witteles

2 years

Dinner with the BEST Editor-in-Chief in the business, #BonnieKy . Thanks for a great visit, Barcelona! @JACCJournals #JaccCardioOnc #ESCCongress

0

9

47

Ronald Witteles

@Ron_Witteles

1 year

Incredible poster by @StanfordMedRes PGY-2 @StefanTorelli at @ACCinTouch #CardioOnc meeting. Beautiful mix of clinical data and basic science, collaborations with @Paul_P_Cheng , @JuneWRhee , @HanZhuMD , @TinaBaykaner45 , @DrMFazal and others. Well done!!! 🎉 @StanfordDeptMed

1

10

46

Ronald Witteles

@Ron_Witteles

6 months

Can you 👀 the 5 @StanfordChiefs in these 📷 from #AHA23 ? That’s @beccatis @KhazanieHeart @MugdhaJoshiMD #KarimSallam and yours truly! Will always be proud to be a member of that special club. @StanfordMedRes @StanfordDeptMed

1

5

47

Ronald Witteles

@Ron_Witteles

2 years

Thank you to our incredible #amyloidosis #clinicaltrials team @StanfordDeptMed ! Privileged to work with such a talented group who are moving the field forward in #amyloidosis . #StanfordAmyloidCenter @KMAlexanderMD @Paul_P_Cheng @RonglihL @TheMahaf @HeartBobH @EldrinL

3

1

46

Ronald Witteles

@Ron_Witteles

6 years

Fantastic presentation by former @StanfordMedRes resident and current @StanfordDeptMed Cardiology fellow @HanZhuMD on her plans to study Immune-checkpoint-inhibitor-associated myocarditis with @SeanM_Wu . Really sophisticated project which will advance the field! @CardioOncology

2

10

46

Ronald Witteles

@Ron_Witteles

4 years

Proud to coauthor this @JACCJournals review on uses and common misuses/errors with PYP scans in diagnosing ATTR #amyloidosis . Incredible team of co-authors! @maz_hanna @MarthaGrogan1 @MathewMaurer @Drjhoffmanmiami @rodney_falk @DorbalaSharmila

2

10

46

Ronald Witteles

@Ron_Witteles

1 year

Thanks to an incredible @StanfordDeptMed #CCU team for a great week and for your wonderful/compassionate patient care! 🫀(Also bonus picture of Levi the Australian Shepherd who joined rounds today…) @StanfordMedRes @StefanTorelli @emmacstmartinMD @DrMFazal @PJuthani @HeartBobH

1

7

45

Ronald Witteles

@Ron_Witteles

4 years

A drug specifically approved for #AL #amyloidosis ! It has been a long time coming, and Would be appropriate for #daratumumab — which has been incredible for so many patients — to be the one. #StanfordAmyloidCenter @KMAlexanderMD @RonglihL @MarthaGrogan1 @maz_hanna @BrettSperryMD

Amyloidosis Research Consortium

@Amyloidosis_ARC

4 years

Game changer for AL amyloidosis -Janssen Pharmaceutical has filed an application with the US Food and Drug Administration seeking approval for Darzalex Faspro to treat light chain (AL) amyloidosis.

0

8

28

1

11

46

Ronald Witteles

@Ron_Witteles

4 years

Wow! Incredible work by @StanfordMedRes IM residency alum and current @StanCVFellows cardiology fellow @David_Ouyang applying machine learning to echocardiography. So proud! Now collaborating with him to apply similar techniques in #amyloidosis . @StanfordDeptMed @HeartBobH

1

7

44

Ronald Witteles

@Ron_Witteles

3 years

We need to push the answer for routine SGLT2 inhibitor prescriptions for HFrEF patients toward "routinely"! Glad for tonight's engagement. @CardioNerdsJC #CardsJC

3

4

45

Ronald Witteles

@Ron_Witteles

3 years

I'm not sure it needs to be this regimented. If K room, get MRA on early. Get SGLT2 inhibitors on early - simple to do, modest BP reduction. BB & ARNI both on early/ASAP as tolerated by BP. Key is not to waste time over many months. So much to do for HF patients! #CardsJC

Amit Goyal MD MAS

@AmitGoyalMD

3 years

What is your preferred order of GDMT in HFrEF? @EldrinL @MarkDrazner @WilcoxHeart @ChonyAlbertMD @DrMarthaGulati @RyanTedfordMD @mapabonp

4

19

97

1

5

45

Ronald Witteles

@Ron_Witteles

4 years

CONGRATULATIONS to the 2020 @StanfordMedRes graduates on the night of their virtual graduation! I’m so proud of you all — what a remarkable class. @StanfordDeptMed @HeartBobH @AJRogers_ICU @PoonamHosamani @WendyCaceresMD @cuttingforstone @KarinaSDelgadoC @trepraja04 @CindyDuong23

3

45

Ronald Witteles

@Ron_Witteles

3 years

@DrNasrien @ManelWatchUS @ShelleyZieroth @DrMarthaGulati @hvanspall @amorrismd @KBreathettMD @kfmarie @JenHoCardiology @noshreza @ersied727 @Drroxmehran Thank you @DrNasrien for calling attention to this. As you may imagine, this is the first time I have seen the list of speakers -- I suspect the same for most/all of us.

3

2

44

Ronald Witteles

@Ron_Witteles

5 years

What a joy to get together with @StanfordMedRes Chief Residents from the last 10 yrs, in advance of tomorrow’s @StanfordMedRes Reunion - what an incredibly talented group! Here’s to celebrating 10 years of program leadership with my friend/colleague Neera Ahuja! @StanfordDeptMed

1

5

44